Activated Protein C Resistance V (APCRV), Plasma
Use
Evaluation of patients with incident or recurrent venous thromboembolism (VTE) and individuals with a family history of VTE. This test helps assess the resistance of plasma to activated protein C, predominantly due to the presence of the factor V Leiden mutation which results in abnormal anticoagulant response.
Special Instructions
Although this assay can be performed independently, it is best utilized within a consultative coagulation test panel with interpretive reporting. Ensure proper preparation and handling of specimens as detailed in the Coagulation Guidelines.
Limitations
The assay is sensitive and specific for inherited APC resistance, primarily due to the factor V Leiden mutation, and will not detect acquired APC resistance. Patient’s preanalytical conditions and specimen preparation are critical. Discrepant results can occur due to liver or allogeneic hematopoietic stem cell transplants, anticoagulants, or sample mix-up.
FDA ApprovedNew York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 13590-5
- 13590-5
- 48591-2
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light-blue top (3.2% sodium citrate) / Polypropylene vial
Collection Instructions
Refer to Coagulation Guidelines. Centrifuge and transfer plasma into a vial, centrifuge again, and freeze immediately at -20°C or ideally at -40°C within 4 hours of collection.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |